Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry.
Chiara CappellettoDavide StolfoNicola OrsiniLina BensonDaniele RodolicoGiuseppe M C RosanoUlf DahlströmGianfranco SinagraLars H LundGianluigi SavaresePublished in: European journal of heart failure (2023)
Obese patients were more likely to receive optimal treatments after adjustment for factors affecting tolerability, suggesting that perceived beyond actual tolerance issues limit GDMT implementation. RASi/ARNi and beta-blockers were associated with lower mortality regardless of obesity, with a greater association between RASi/ARNi and lower cardiovascular death in obese versus non-obese patients when considering competing risk.
Keyphrases
- obese patients
- bariatric surgery
- heart failure
- weight loss
- gastric bypass
- roux en y gastric bypass
- metabolic syndrome
- primary care
- healthcare
- insulin resistance
- depressive symptoms
- physical activity
- social support
- randomized controlled trial
- open label
- mental health
- electronic health record
- cardiovascular disease
- weight gain
- quality improvement
- deep learning
- double blind
- machine learning
- glycemic control
- artificial intelligence